**Appendix H: Gabapentin Meta-analyses**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Outcome and subgroup | Studies | Participants | I2 | Risk Ratio (M-H, Fixed, 95% CI) | Risk Ratio (M-H, Random, 95% CI) |
| 3.1 Prevalence of any pain at 3 mo., drug ≤24h, mixed surgical procedures | 2 | 156 | 0 | 1.02 [0.79, 1.30] | 1.04 [0.82, 1.32] |
| 3.2 Prevalence of any pain at 3 mo., drug >24h, mixed surgical procedures | 4 | 200 | 0 | 0.96 [0.75, 1.24] | 0.97 [0.75, 1.25] |
| 3.3 Prevalence of any pain at 6 mo., drug >24h, mixed surgical procedures | 3 | 511 | 0 | 1.07 [0.81, 1.42] | 1.06 [0.81, 1.40] |
| 3.4 Prevalence of any pain at 3 mo., thoracotomy | 2 | 196 | 0 | 1.03 [0.84, 1.27] | 1.03 [0.84, 1.27] |

**Analysis 3.1. Gabapentin versus placebo comparisons, prevalence of any pain at 3 months (drug administration ≤ 24 hours)**

****

**Analysis 3.2. Gabapentin versus placebo comparisons, prevalence of any pain at 3 months (drug administration > 24 hours)**

****

**Analysis 3.3. Gabapentin versus placebo comparisons, prevalence of any pain at 6 months (drug administration > 24 hours)**

****

**Analysis 3.4. Gabapentin versus placebo comparisons, prevalence of any pain at 3 months (thoracotomy)**

****